Literature DB >> 24596899

Fostering directly observed treatment in tuberculosis: a program manager's perspective.

Saurabh Rambiharilal Shrivastava1, Prateek Saurabh Shrivastava1, Jegadeesh Ramasamy1.   

Abstract

Global Tuberculosis (TB) report (2013) has revealed that an estimated 8.6 million people developed TB of which, India accounts for almost 26% of the cases. These estimates clearly suggest that the country's efforts to achieve Millennium Development Goal 6 by 2015 have not delivered the desired output. In India, the TB prevention and control activities are supervised and implemented under the Revised National TB Control Program (RNTCP), which recognizes that implementation of a good quality Directly Observed Treatment with Short course chemotherapy (DOTS) is the first priority for TB control. Directly Observed Treatment (DOT) is the key element in DOTS strategy, in which a DOT provider insures and supports the patients in consuming their drugs throughout the course of treatment. In order to meet the country's vision to achieve universal access of TB care, the RNTCP has launched a "treatment adherence scheme" (public-private partnership scheme). Further, an evidence-based integrated strategy should be formulated for addressing the identified barriers which advocates universal administration of DOT. To conclude, DOT in RNTCP insures long-term adherence to the treatment, with right drugs in right doses, at right intervals and thus plays an indispensable role in improving the outcome indicators of the program and the quality of life in patients.

Entities:  

Keywords:  Directly Observed Treatment (DOT); India; Revised National Tuberculosis Control Program (RNTCP),; Tuberculosis

Year:  2013        PMID: 24596899      PMCID: PMC3937952          DOI: 10.15171/ijhpm.2014.11

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


  6 in total

1.  The use of videophone for directly observed therapy for the treatment of tuberculosis.

Authors:  Margaret A Gassanov; Linda J Feldman; Adrian Sebastian; Marnie J Kraguljac; Elizabeth Rea; Barbara Yaffe
Journal:  Can J Public Health       Date:  2013-05-14

2.  First do no harm--adverse events, drug intolerance, and hepatotoxicity: how can we not justify directly observed therapy for treating tuberculosis?

Authors:  Barbara J Seaworth; Lisa Y Armitige; David E Griffith
Journal:  Clin Infect Dis       Date:  2013-06-27       Impact factor: 9.079

3.  Can DOTS improve quality of life among patients with pulmonary tuberculosis?

Authors:  Wei-Sheng Chung; Chi-Rong Li
Journal:  Int J Tuberc Lung Dis       Date:  2013-03       Impact factor: 2.373

4.  A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

5.  Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania.

Authors:  Abdallah Mkopi; Nyagosya Range; Fred Lwilla; Saidi Egwaga; Alexander Schulze; Eveline Geubbels; Frank van Leth
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

6.  Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt & challenges ahead.

Authors:  Surendra K Sharma; Alladi Mohan; L S Chauhan; J P Narain; P Kumar; D Behera; K S Sachdeva; Ashok Kumar; Priyanka Agarwal; N T Awadh; Avi Bansal; S Baruah; Pranab Baruwa; V H Balasangameshwara; Rani Balasubramanian; A K Bhardwaj; Salil Bhargav; Sarabjit Chadha; V K Chaddha; Manpreet Chhatwal; A L Da Costa; D P Dash; Jaydip Dep; Saroj Dhingra; S Dhooria Harmeet; T R Frieden; Anil Garg; Reuben Granich; Vinay Gulati; Deepak Gupta; Dheeraj Gupta; K B Gupta; K N Gupta; A K Janmeja; M S Jawahar; S L Jethani; S K Jindal; K R John; O P Kalra; V P Kalra; A T Kannan; S Kayshap; G Keshav Chander; S S Khushwa; R S Kushwaha; Vinod Kumar; B Laskar; K R Leela Itty Amma; A T Leuva; K Maitra Malay; A M Mesquita; Thomas Mathew; Yamuna Mundade; Radha Munje; Somil Nagpal; C Nagaraja; Sanjeev Nair; O R Narayanan; C N Paramasivan; Malik Parmar; Rajendra Prasad; A C Phukan; Raj Prasanna; Anil Purty; Ranjani Ramachandran; Rajeswari Ramachandran; C Ravindran; H R Reddy Raveendra; S Sahu; Rohit Sarin; Soumya Sarkar; K C Sarma; P Saxena; Shruti Sehgal; N Sharath; Geetanjali Sharma; Nandini Sharma; P K Shridhar; R S Shukla; Om Singh; N Tombi Singh; Varinder Singh; Rupak Singla; Neena Sinha; Pranay Sinha; Sanjay Sinha; Rajesh Solanki; A Sreenivas; S Srinath; Kandi Subhakar; J C Suri; Palash Talukdar; Jamie Tonsing; S P Tripathy; Preetish Vaidyanathan; R P Vashist; K Venu
Journal:  Indian J Med Res       Date:  2013-02       Impact factor: 2.375

  6 in total
  2 in total

1.  Association of serum leptin levels and pulmonary tuberculosis: a meta-analysis.

Authors:  Mao Ye; Lv-Fei Bian
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

2.  Assessing the utility of contact tracing in reducing the magnitude of tuberculosis.

Authors:  Saurabh R Shrivastava; Prateek S Shrivastava; Jegadeesh Ramasamy
Journal:  Infect Ecol Epidemiol       Date:  2014-10-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.